secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045804
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity Q3 net loss $29.8M ($0.70/sh); VIKTORIA-1 wild-type cohort 100% enrolled
--------------------------------------------------------------------------------

- PIK3CA wild-type cohort of VIKTORIA-1 100% enrolled; topline data expected late Q1 2025 or Q2 2025.
- Celcuity reports Q3 2024 net loss $29.8M ($0.70/sh) vs $18.4M ($0.83/sh) in Q3 2023.
- R&D expenses $27.6M, up from $17.5M; total operating expenses $30.1M.
- Cash, cash equivalents and investments ~$264M at end of Q3 2024, expected to fund through 2026.
- VIKTORIA-2 Phase 3 first patient enrollment expected Q2 2025; Phase 1b/2 mCRPC data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224045804/0001493152-24-045804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315224045804/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer